ArticleFrontiers in immunology2026
Breaking the barrier: oral tacrolimus plus apremilast rescues acute generalized pustular psoriasis with severe comorbidities-a case report.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Generalized pustular psoriasis (GPP) is a severe disease. Treatment options for refractory cases with multiple comorbidities remain limited. This report describes a 72-year-old female patient with a 10-year history of plaque psoriasis. The patient experienced recurrent episodes of GPP over the past year, complicated by type 2 diabetes mellitus, hyperlipidemia, hypertension, stage 3 chronic kidney disease (CKD), and pulmonary interstitial fibrosis. Multiple prior therapies had failed, and several conventional medications were contraindicated due to comorbidities. Additionally, the patient refused further treatment with pesolimab. Oral tacrolimus combined with apremilast was administered, resulting in resolution of skin lesions and improvement in renal function.To our knowledge, this is among the first reported cases of successful treatment for recurrent acute GPP, especially refractory acute GPP, using oral tacrolimus in combination with apremilast. The observed therapeutic response suggests potential shared immunological pathways between acute GPP and CKD, which may be influenced by this combination therapy, contributing to improvements in both skin manifestations and renal function. This case provides a valuable reference for optimizing treatment regimens and investigating mechanisms in refractory GPP. Further studies are required to enhance therapeutic efficacy and minimize adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.